# Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder

> **NCT02557971** · — · COMPLETED · sponsor: **Allergan** · enrollment: 315 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** onabotulinumtoxinA

## Key facts

- **NCT ID:** NCT02557971
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2016-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02557971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02557971, "Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02557971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*